Výsledky vyhledávání - "John K. Diep"

Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis

Autor: John K. Diep, Rosie Z. Yu, Nicholas J. Viney, Eugene Schneider, Shuling Guo, Scott Henry, Brett Monia, Richard Geary, Yanfeng Wang

Publikováno v: British Journal of Clinical Pharmacology. 88:5389-5398

Transthyretin-mediated amyloidosis is a progressive and fatal disease caused by the build-up of misfolded transthyretin (TTR) protein. Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotide targeting TTR m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87cf398f01a3cd3a211509b8e0991145
https://doi.org/10.1111/bcp.15468

Zobrazit plný text záznamu

Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model

Autor: Cely S. Abboud, Gauri G. Rao, Patrick O. Hanafin, John K. Diep, Keith S Kaye, Estefany Garcia, Jian Li, Tony Velkov, Rajnikant Sharma

Publikováno v: Clinical Pharmacology and Therapeutics

Mounting antimicrobial resistance to carbapenemase-producing Klebsiella pneumoniae (CPKP) highlights the need to optimize currently available treatment options. The objective of this study was to explore alternative dosing strategies that limit the e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70f56976d557f721f132009861e24ad0
https://doi.org/10.1002/cpt.2197

Zobrazit plný text záznamu

Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides

Autor: Yanfeng Wang, John K. Diep, Rosie Z. Yu, Eunju Hurh, Ewa Karwatowska‐Prokopczuk, Eugene Schneider, Scott Henry, Sanjay Bhanot, Richard S. Geary

Publikováno v: Journal of clinical pharmacologyReferences.

The pharmacokinetics (PK) of 2'-O-methoxyethyl and phosphorothioate antisense oligonucleotides (ASOs), with or without N-acetyl galactosamine conjugation, have been well characterized following subcutaneous or intravenous drug administration. However

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60c46dc27f55a183d4b9afa6f7b0ecf
https://pubmed.ncbi.nlm.nih.gov/35801818

Zobrazit plný text záznamu

Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae

Autor: Rajnikant Sharma, Estefany Garcia, John K. Diep, Vince H. Lee, Faisal Minhaj, Brian Jermain, Evelyn J. Ellis-Grosse, Cely S. Abboud, Gauri G. Rao

Publikováno v: International journal of antimicrobial agents. 59(4)

Determining the role of the immune response in preventing antimicrobial resistance and optimising antibiotic regimens against carbapenemase-producing Klebsiella pneumoniae is a research gap that exists and needs to be further explored. The objective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83d49a73ba93e7913c7b44494b12e86d
https://pubmed.ncbi.nlm.nih.gov/35288260

Zobrazit plný text záznamu

Mechanism‐Based Disease Progression Model Describing Host‐Pathogen Interactions During the Pathogenesis of Acinetobacter baumannii Pneumonia

Autor: Gauri G. Rao, John K. Diep, Thomas A. Russo

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

The emergence of highly resistant bacteria is a serious threat to global public health. The host immune response is vital for clearing bacteria from the infected host; however, the current drug development paradigm does not take host-pathogen interac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f97caabb42b367970a153b915b36e71
http://europepmc.org/articles/PMC6118322

Zobrazit plný text záznamu

Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii

Autor: Roger L. Nation, Jürgen B. Bulitta, Jian Li, Patricia N. Holden, Alan Forrest, Brian T. Tsuji, Neang S. Ly, Gauri G. Rao, John K. Diep

Publikováno v: International Journal of Antimicrobial Agents. 48:331-336

The prevalence of heteroresistant Acinetobacter baumannii is increasing. Infections due to these resistant pathogens pose a global treatment challenge. Here, the pharmacodynamic activities of polymyxin B (PMB) (2–20 mg/L) and tigecycline (0.15–4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::723647b2738d32e321d2ecdc2f8412c3
https://doi.org/10.1016/j.ijantimicag.2016.06.006

Zobrazit plný text záznamu

Comparison of the composition and in vitro activity of polymyxin B products

Autor: Jenna Covelli, Donna M. Ruszaj, Jian Li, Gauri G. Rao, John K. Diep, Keith S Kaye, Rajnikant Sharma, Robert M. Straubinger

Publikováno v: International journal of antimicrobial agents. 52(3)

A number of companies manufacture polymyxin B using United States Pharmacopeia (USP) metrics, rather than chemical composition, to report biological activity. Given that polymyxin B contains several different components, it is unknown whether pharmac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3073f74a1c74253fe18abb28a426f8ee
https://pubmed.ncbi.nlm.nih.gov/29807163

Zobrazit plný text záznamu

Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae

Autor: Rajnikant Sharma, Cely S. Abboud, Evelyn J. Ellis-Grosse, Gauri G. Rao, John K. Diep

Publikováno v: Antimicrobial Agents and Chemotherapy

ZTI-01 (fosfomycin for injection) is a broad-spectrum antibiotic with a novel mechanism of action and is currently under development in the United States for treatment of complicated urinary tract infections. Globally, fosfomycin and polymyxin B are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49936c0a43b074c1b9b0cc01dc48679a
http://europepmc.org/articles/PMC5786778

Zobrazit plný text záznamu

In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae

Autor: Cely S. Abboud, Keith S Kaye, Jussimara Monteiro, Dennis Huang, Brenda Yu, Jason M. Pogue, Rajnikant Sharma, Gauri G. Rao, John K. Diep, Michael N. Dudley

The multidrug resistance profiles of Klebsiella pneumoniae carbapenemase (KPC) producers have led to increased clinical polymyxin use. Combination therapy with polymyxins may improve treatment outcomes, but it is uncertain which combinations are most

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1cf733ea3a491b44f35d79df5e8ac46
https://europepmc.org/articles/PMC5487624/

Zobrazit plný text záznamu

Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes

Autor: Saloni Patel, Cely S. Abboud, Keith S. Kaye, Neang S. Ly, Jian Li, Gauri G. Rao, John K. Diep, Jason M. Pogue, Rajnikant Sharma

Publikováno v: International journal of antimicrobial agents. 49(2)

Combination therapy provides a useful therapeutic approach to overcome resistance until new antibiotics become available. In this study, the pharmacodynamics, including the morphological effects, of polymyxin B (PMB) and meropenem alone and in combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9854eb29e8e32395cd18bfe6ea8cfdd1
https://pubmed.ncbi.nlm.nih.gov/28040408

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání